Oncotarget

Research Papers:

Adhesion- and stress-related adaptation of glioma radiochemoresistance is circumvented by β1 integrin/JNK co-targeting

Anne Vehlow, Erik Klapproth, Katja Storch, Ellen Dickreuter, Michael Seifert, Antje Dietrich, Rebecca Bütof, Achim Temme and Nils Cordes _

PDF  |  HTML  |  Supplementary Files  |  How to cite  |  Order a Reprint

Oncotarget. 2017; 8:49224-49237. https://doi.org/10.18632/oncotarget.17480

Metrics: PDF 1077 views  |   HTML 2605 views  |   ?  


Abstract

Anne Vehlow1,2,10,11, Erik Klapproth1, Katja Storch1,3, Ellen Dickreuter1, Michael Seifert4,5, Antje Dietrich1,8,9, Rebecca Bütof1,5,6,8,9, Achim Temme7,8,9 and Nils Cordes1,3,6,8,9

1OncoRay, National Center for Radiation Research in Oncology, Faculty of Medicine and University Hospital Carl Gustav Carus, Technische Universität Dresden, Helmholtz-Zentrum Dresden, Rossendorf, PF 41, 01307, Dresden, Germany

2Helmholtz-Zentrum Dresden, Rossendorf, Institute of Radiopharmaceutical Cancer Research, 01328, Dresden, Germany

3Helmholtz-Zentrum Dresden, Rossendorf, Institute of Radiooncology, OncoRay, 01328, Dresden, Germany

4Institute for Medical Informatics and Biometry, Faculty of Medicine Carl Gustav Carus, Technische Universität Dresden, 01307, Dresden, Germany

5National Center for Tumor Diseases (NCT), Partner Site Dresden, 69192, Heidelberg, Germany

6Department of Radiotherapy and Radiation Oncology, Faculty of Medicine and University Hospital Carl Gustav Carus, Technische Universität Dresden, PF 50, 01307, Dresden, Germany

7Department of Neurosurgery, Section of Experimental Neurosurgery/Tumor Immunology, Faculty of Medicine and University Hospital Carl Gustav Carus, Technische Universität Dresden, 01307, Dresden, Germany

8German Cancer Consortium (DKTK), Parter Site Dresden, 69192, Heidelberg, Germany

9German Cancer Research Center (DKFZ), 69192, Heidelberg, Germany

10Current address: National Center for Tumor Diseases (NCT), Partner Site Dresden, 69192, Heidelberg, Germany

11Current address: German Cancer Consortium (DKTK), Parter Site Dresden, and German Cancer Research Center (DKFZ), 69192, Heidelberg, Germany

Correspondence to:

Nils Cordes, email: nils.cordes@oncoray.de

Keywords: β1 integrin, JNK, radiochemoresistance, GBM stem-like cells, orthotopic GBM mouse model

Received: February 24, 2017     Accepted: April 12, 2017     Published: April 27, 2017

ABSTRACT

Resistance of cancer stem-like and cancer tumor bulk cells to radiochemotherapy and destructive infiltration of the brain fundamentally influence the treatment efficiency to cure of patients suffering from Glioblastoma (GBM). The interplay of adhesion and stress-related signaling and activation of bypass cascades that counteract therapeutic approaches remain to be identified in GBM cells. We here show that combined inhibition of the adhesion receptor β1 integrin and the stress-mediator c-Jun N-terminal kinase (JNK) induces radiosensitization and blocks invasion in stem-like and patient-derived GBM cultures as well as in GBM cell lines. In vivo, this treatment approach not only significantly delays tumor growth but also increases median survival of orthotopic, radiochemotherapy-treated GBM mice. Both, in vitro and in vivo, effects seen with β1 integrin/JNK co-inhibition are superior to the monotherapy. Mechanistically, the in vitro radiosensitization provoked by β1 integrin/JNK targeting is caused by defective DNA repair associated with chromatin changes, enhanced ATM phosphorylation and prolonged G2/M cell cycle arrest. Our findings identify a β1 integrin/JNK co-dependent bypass signaling for GBM therapy resistance, which might be therapeutically exploitable.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 17480